Market Place
Sourcing Support
Molecular Templates Receives Notice of Delisting for Failure
19 Dec 2024 //
GLOBENEWSWIRE
Molecular Templates Faces Nasdaq Deficiency For Late Form 10-Q
02 Dec 2024 //
GLOBENEWSWIRE
Molecular Templates Reports Q2 2024 Financial Results And Corporate Update
14 Aug 2024 //
GLOBENEWSWIRE
Molecular Templates, Inc. Provides Interim Update
03 Jun 2024 //
GLOBENEWSWIRE
Molecular Templates Reports Q1 2024 Financial Results, Corporate Update
15 May 2024 //
GLOBENEWSWIRE
Molecular Templates Presents MT-6402 Interim Data at AACR
09 Apr 2024 //
GLOBENEWSWIRE
Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results
29 Mar 2024 //
GLOBENEWSWIRE
Molecular Templates Announces $9.5 Million Private Placement Offering
28 Mar 2024 //
GLOBENEWSWIRE
Molecular Templates, Inc. Provides Interim Update
04 Mar 2024 //
GLOBENEWSWIRE
Molecular Templates to Present at Oppenheimer 34th Annual Conference
08 Feb 2024 //
GLOBENEWSWIRE
Molecular Templates, Inc. Reports Third Quarter 2023 Financial Results
13 Nov 2023 //
GLOBENEWSWIRE
Molecular Announces First Patient Dosed in Phase 1 Trial Evaluating MT-8421
02 Nov 2023 //
GLOBENEWSWIRE
Molecular Templates to Participate in Upcoming Investor Conferences
01 Nov 2023 //
GLOBENEWSWIRE
Molecular Templates Announces the Appointment of Dr. Maurizio Voi as CMO
28 Sep 2023 //
GLOBENEWSWIRE
Molecular Templates Announces 1-for-15 Reverse Stock Split
11 Aug 2023 //
GLOBENEWSWIRE
Molecular Templates, Inc. Reports Second Quarter 2023 Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
Molecular Templates Announces Executive Leadership Changes
02 Aug 2023 //
GLOBENEWSWIRE
Molecular Templates Announces Up to $40 Million Private Placement Offering
13 Jul 2023 //
GLOBENEWSWIRE
More layoffs at Molecular Templates as it pays debts to survive
20 Jun 2023 //
FIERCE BIOTECH
Molecular Templates Announces Debt Payoff and Restructuring
16 Jun 2023 //
GLOBENEWSWIRE
Molecular Templates is back in action after brief FDA hold
02 Jun 2023 //
FIERCE BIOTECH
Molecular Templates Announces FDA Removal of Partial Clinical Hold in MT-0169
01 Jun 2023 //
GLOBENEWSWIRE
Molecular Templates to Present on Phase I Dose Escalation Study of MT-6402
26 May 2023 //
GLOBENEWSWIRE
Molecular Templates, Inc. Reports 1Q 2023 FYR Results and Business Update
15 May 2023 //
GLOBENEWSWIRE
FDA puts Molecular Templates` drug on partial hold
11 Apr 2023 //
FIERCE BIOTECH
Molecular Templates Announces Partial Clinical Hold for Phase 1 Study of MT-0169
07 Apr 2023 //
GLOBENEWSWIRE
Molecular Templates halves headcount as cash crunch looms
01 Apr 2023 //
FIERCE BIOTECH
Molecular Templates Reports 4Q Financial Results 2022 & Business Update
30 Mar 2023 //
GLOBENEWSWIRE
Molecular Templates Announces IND Acceptance by FDA for MT-8421 ETB Program
09 Mar 2023 //
GLOBENEWSWIRE
Molecular Templates Announces Participation in Upcoming Conferences
01 Mar 2023 //
GLOBENEWSWIRE
Molecular Templates to Present Interim Results on MT-5111
02 Dec 2022 //
GLOBENEWSWIRE
Molecular Templates, Inc. to Present Fireside Chats at Two Investor Conferences
23 Nov 2022 //
GLOBENEWSWIRE
Molecular Templates, Inc. Reports Third Quarter 2022 Financial Results
10 Nov 2022 //
GLOBENEWSWIRE
Molecular Templates, Inc. to Present Interim Data and Host R&D Day
04 Nov 2022 //
GLOBENEWSWIRE
Molecular Templates, Inc. Reports Second Quarter 2022 Financial Results
11 Aug 2022 //
GLOBENEWSWIRE
Molecular Templates Presentations at the 2022 ASCO in PD-L1 and HER2 Programs
06 Jun 2022 //
GLOBENEWSWIRE
Molecular Templates to Present at Upcoming Investor Conferences
17 May 2022 //
GLOBENEWSWIRE
Molecular Templates, Inc. Reports First Quarter 2022 Financial Results
12 May 2022 //
GLOBENEWSWIRE
Molecular Templates Presentations at the AACR
12 Apr 2022 //
GLOBENEWSWIRE
Molecular Templates to Host Webinar on Unique Approach to IO for Solid Tumors
08 Apr 2022 //
GLOBENEWSWIRE
Molecular Templates, Inc. Reports Fourth Quarter 2021 Financial Results
28 Mar 2022 //
GLOBENEWSWIRE
Molecular Templates Strengthens Board of Directors and Management Team
02 Mar 2022 //
GLOBENEWSWIRE
Molecular Templates to Present at the Upcoming Investor Conferences
01 Mar 2022 //
GLOBENEWSWIRE
Molecular Announces Fast Track Designation Granted by FDA for MT-6402
18 Nov 2021 //
GLOBENEWSWIRE
Molecular Templates up 13% following large share purchase from Swiss firm
24 Sep 2021 //
SEEKINGALPHA
Molecular Templates to Present at Oppenheimer Fall Healthcare & MedTech Summit
20 Sep 2021 //
GLOBENEWSWIRE
Molecular Templates Announces Dosing of First Subject in Ph 1 Study of MT-6402
09 Jul 2021 //
GLOBENEWSWIRE
Molecular Templates to Present at the Ladenburg Thalmann Healthcare Conference
06 Jul 2021 //
GLOBENEWSWIRE
Molecular Announces Poster Presentations on its Engineered Toxin Bodies
13 Apr 2021 //
GLOBNEWSWIRE
In 1-2 punch, Molecular Templates cuts first-gen candidate and loses Big Pharma
07 Apr 2021 //
ENDPTS
Molecular Templates Reports Fourth Quarter 2020 Financial Results
18 Mar 2021 //
GLOBENEWSWIRE
Molecular Announces Pricing of $75.9 Million Public Equity Offering
18 Feb 2021 //
GLOBENEWSWIRE
Bristol Myers pens $1.3B biobucks pact with Molecular, axes Celgene CAR-T asset
16 Feb 2021 //
FIERCE BIOTECH
Molecular Templates, BMS Enter Strategic Research Pact
12 Feb 2021 //
GLOBENEWSWIRE
Molecular Templates, Inc. Provides Update on MT-5111 Phase 1 Study
21 Dec 2020 //
GLOBENEWSWIRE
Molecular Templates, Inc. Raises $43 Million in Gross Proceeds Through
20 Jul 2020 //
GLOBENEWSWIRE
Molecular Templates to Prioritize Next-Generation ETB Candidates
05 Apr 2020 //
BIOSPACE
Molecular Templates to assume full rights to TAK-169 including taking control
05 Apr 2020 //
PHARMABIZ
Shares in Molecular Templates surge after announcement of Takeda collaboration
20 Sep 2018 //
PHARMA FILE
